ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. - Wikidata - wikimedia - TriplyDB

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

http://www.wikidata.org/entity/Q35033300

about

Evolutionary dynamics of cancer in response to targeted combination therapy ALK inhibitors in non-small cell lung cancer: the latest evidence and developments Preclinical Murine Models for Lung Cancer: Clinical Trial Applications From tissue to molecular phenotyping: pre-analytical requirements heidelberg experience Will kinase inhibitors make it as glioblastoma drugs?Apoptotic agents Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy Identification of targetable FGFR gene fusions in diverse cancers.Systematic identification of combinatorial drivers and targets in cancer cell lines β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.Open-access synthetic spike-in mRNA-seq data for cancer gene fusions.Transforming fusions of FGFR and TACC genes in human glioblastoma.Discovering and understanding oncogenic gene fusions through data intensive computational approaches Use of big data in drug development for precision medicine.Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.Evaluating translocation gene fusions by SNP array data.Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.Collateral Lethality: A new therapeutic strategy in oncology Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers Mouse model for ROS1-rearranged lung cancer Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung.Molecular diagnosis of intrahepatic cholangiocarcinoma.Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.An emerging toolkit for targeted cancer therapies.Translating cancer 'omics' to improved outcomes.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models Tyrosine kinase inhibitors in lung cancer.MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents.Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils ALK-immunoreactive neoplasms.

P2860

Q21128788-4EFCB050-3F20-433C-81D9-453C8EE6AD60 Q26769879-24F6CEF0-3B67-4FC3-8092-750C784EF3D8 Q26863474-8AC070E1-21C2-4B99-8ACD-B3BF89D39162 Q26864637-9E23D1E5-9D96-450E-AF84-A72475BD880A Q27012684-6B3B3528-CE76-43D0-99C9-81701F991FCB Q27016160-8B03FFFC-FD64-4870-8CFF-FE1C2C166D2F Q27682798-7B0ED83C-EEAD-41DE-A243-7229172223B7 Q27852147-511F90C8-1A1A-4EC2-AA58-A479B8DAB24F Q28486051-BDF10CA3-82E3-49CE-8425-3B54A219D98F Q30427521-E08454E0-E782-46EA-B1EF-EDC8E06118F8 Q30486741-10668D4A-D2AB-482D-BAD8-67A2CDE31B02 Q30487334-DD831444-5D1E-44B8-BF53-3002F3D8065D Q30540467-7D63DF27-986A-43CC-B405-4831F2A0B9ED Q31083417-A77ED7D7-175C-49DE-92C2-5DF5144DCE18 Q31115480-796B155B-E1B9-4800-BA7C-D48188DAEB8D Q33636098-262007C7-C4C2-4C59-A5FE-EAB4C5A53017 Q33776852-60308C0E-D473-45EA-B2FE-59F1439D4074 Q33865475-24B23E07-71DB-47B6-9F6A-5DEB4B6548AF Q34132911-EB299E43-040E-4B7C-8D76-B8811493BC94 Q34356166-D3248A56-4906-4FCA-904C-479CDADD5CA1 Q34362370-7E470EAA-ABFF-410A-A325-8BEC7C6799DD Q34513800-E31AB7DF-6C7C-404C-9D90-AB35731C5F01 Q34522899-D62822F7-DBC5-4CA5-B2D7-882448300AD7 Q34525966-A3295C13-27CF-4C02-9FEE-1DCCDF3D3419 Q34589721-31F3AFBF-A544-4CDA-9F24-EE70D4D9C6A0 Q34633416-4B6BA9D2-D119-40CA-B467-0E91ADA96BD7 Q34662576-4144798B-094A-4C70-8516-940B72F8CA93 Q35287629-D8731EC7-34B4-40C1-9E52-33D07FB411B1 Q35592221-F544C472-F924-45AD-910F-88D4D44AF31F Q35671292-5F5D0DB7-71B9-4578-90CB-9CE7CD4BF5F6 Q35694357-8B6DDCA1-1818-489D-AC06-65003D0F468F Q35694365-448C5F89-F210-419A-91CF-5D7A110DB084 Q35858617-AA45A184-2CF2-4910-804C-F21F33A707F8 Q35908430-B5188891-1C46-4B88-BAC1-88BBEAAFDEEE Q35951821-B46198CD-8A6A-4EE9-9817-1CECC8CF66F4 Q35967385-45A0B276-4842-43FF-BFEE-3F56C102BB77 Q36020891-7D3BB73D-FC67-4EB6-8E64-230D62E49D9A Q36021866-2C3549E3-B978-4647-B6DE-C617C0AFD920 Q36038823-ED2385E6-8E70-4A89-A722-4612DC49873B Q36092957-0833C915-729A-4B7F-95AD-70DC117DF650

P2860

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

http://www.wikidata.org/entity/Q35033300

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

@ast

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

@en

type

label

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

@ast

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

@en

prefLabel

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

@ast

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

@en

P1433

Q35033300-A1626F90-E1A1-453E-81BB-6728B80EF9DF

P1476

Q35033300-DE1A1148-9560-45C6-90C1-2A814656F4EE

P2093

Q35033300-17497636-7C8A-404A-AEB5-89897F2026AB

Q35033300-CD3DBA6A-4949-4EC6-9E26-37B9426DEC2E

P2860

Q35033300-049C490F-0EA8-42E1-ACF9-2675289D0EF8

Q35033300-04A3F971-1734-49CC-B088-D37F3E8EED82

Q35033300-069F6537-5D59-48B5-AC57-696349C1F40F

Q35033300-07494F86-8128-4E4F-855F-085D25BF7F99

Q35033300-0E984918-6813-40FF-AAA4-82C1668E4D25

Q35033300-15164566-DD2F-4B29-898F-F124F277A586

Q35033300-15DBDE0D-B6BD-41D4-97E5-858D5AAF98F9

Q35033300-208A28F9-EFAE-4C99-9A83-DBB2D3780EB5

Q35033300-343EF485-5C3F-4EE9-86FA-3CD27382945C

Q35033300-38472AEE-4701-46A3-8140-7314A34DF1FE

P304

Q35033300-CEBF9678-1D7B-48E2-8297-9A542CE0CB75

P31

Q35033300-05ea8865-6525-417a-9e92-1d1af7b9c149

Q35033300-46B1128F-EA09-47B5-9651-1A5664D372C0

P356

Q35033300-FC50539F-F2F0-40F9-AE3F-7ECDAFD48558

P433

Q35033300-DB915474-9DFD-49BA-A3E5-F29CBB4B495C

P478

Q35033300-6F55B998-6C08-4907-9ADE-20E531ADC7BD

P577

Q35033300-099D0F8C-276D-4D7A-AB98-2445CEC80DF9

P5875

Q35033300-E20F4762-BADF-4252-B05D-F063EC94DA61

P698

Q35033300-E19089B9-2214-4A4F-8FA9-A22E0A1EA8F6

P932

Q35033300-1207EAA1-0218-4C42-90E1-DE760F86BA96

P356

J.CCR.2010.11.033

P1433

P1476

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

@en

P2093

David E Gerber

http://www.w3.org/2001/XMLSchema#string

John D Minna

http://www.w3.org/2001/XMLSchema#string

P2860

A small-cell lung cancer genome with complex signatures of tobacco exposure

Network of Cancer Genes: a web resource to analyze duplicability, orthology and network properties of cancer genes

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer

Somatic mutations affect key pathways in lung adenocarcinoma

Characterizing the cancer genome in lung adenocarcinoma.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

P304

548-551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2010.11.033

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49681680

http://www.w3.org/2001/XMLSchema#string

P698

21156280

http://www.w3.org/2001/XMLSchema#string

P932

3110762

http://www.w3.org/2001/XMLSchema#string